Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

MaddogMaddi Mar. 31 at 11:08 PM

$KALA America! 🇺🇸

0 · Reply

bcw7734 Mar. 31 at 10:36 PM

$KALA they will indeed have to file this form tomorrow. Sorry to everyone waiting for earnings news today. Looks like abother 2 weeks of pain.

1 · Reply

JustDoItMF Mar. 31 at 10:33 PM

$KALA delaying earnings means we have 2 more weeks. Let's Go!!

0 · Reply

Threescompany Mar. 31 at 10:26 PM

$KALA oh of course I’m blocked by that retard

1 · Reply

JustDoItMF Mar. 31 at 10:23 PM

$KALA blocked 🤡

0 · Reply

Frankthetank747 Mar. 31 at 9:57 PM

$KALA :( No comment!

0 · Reply

Threescompany Mar. 31 at 8:39 PM

$KALA no earnings and no good news pump. Reverse split soon

0 · Reply

Rbfotoart Mar. 31 at 8:29 PM

$KALA

0 · Reply

Threescompany Mar. 31 at 8:28 PM

$KALA lol

1 · Reply

NorthernMonkey1 Mar. 31 at 7:53 PM

$CXAI $KALA expecting an AH to rememeber, loaded and ready for it! 🔥 🚀

1 · Reply

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Mar 30, 2026, 8:31 AM EDT - 1 day ago

EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch

Mar 18, 2026, 9:00 AM EDT - 13 days ago

Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 8:15 AM EDT - 13 days ago

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 11, 2026, 11:18 AM EDT - 20 days ago

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Mar 11, 2026, 6:30 AM EDT - 20 days ago

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Mar 9, 2026, 6:20 AM EDT - 22 days ago

Stock Trend Capital Provides Younet AI Investment Update

Mar 4, 2026, 6:30 AM EST - 27 days ago

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

Jan 5, 2026, 4:10 PM EST - 3 months ago

KALA BIO Settles Approximately $10.6 million of Debt

Dec 4, 2025, 10:45 AM EST - 4 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Sep 29, 2025, 12:00 PM EDT - 6 months ago

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Aug 8, 2025, 8:00 AM EDT - 8 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:00 AM EDT - 8 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 9, 2025, 8:00 AM EDT - 9 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

May 29, 2025, 8:00 AM EDT - 10 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

May 14, 2024, 4:05 PM EDT - 2 years ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 29, 2022, 8:30 AM EST - 3 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022, 10:17 AM EDT - 4 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

MaddogMaddi Mar. 31 at 11:08 PM

$KALA America! 🇺🇸

0 · Reply

bcw7734 Mar. 31 at 10:36 PM

$KALA they will indeed have to file this form tomorrow. Sorry to everyone waiting for earnings news today. Looks like abother 2 weeks of pain.

1 · Reply

JustDoItMF Mar. 31 at 10:33 PM

$KALA delaying earnings means we have 2 more weeks. Let's Go!!

0 · Reply

Threescompany Mar. 31 at 10:26 PM

$KALA oh of course I’m blocked by that retard

1 · Reply

JustDoItMF Mar. 31 at 10:23 PM

$KALA blocked 🤡

0 · Reply

Frankthetank747 Mar. 31 at 9:57 PM

$KALA :( No comment!

0 · Reply

Threescompany Mar. 31 at 8:39 PM

$KALA no earnings and no good news pump. Reverse split soon

0 · Reply

Rbfotoart Mar. 31 at 8:29 PM

$KALA

0 · Reply

Threescompany Mar. 31 at 8:28 PM

$KALA lol

1 · Reply

NorthernMonkey1 Mar. 31 at 7:53 PM

$CXAI $KALA expecting an AH to rememeber, loaded and ready for it! 🔥 🚀

1 · Reply

JustDoItMF Mar. 31 at 7:47 PM

$KALA but i love that in a way because that's when it shoots to outer space lets see

0 · Reply

We_the_People_Fight Mar. 31 at 7:44 PM

$KALA so quiet. Everyone gave up on this stock. God bless

1 · Reply

BlazingStocks Mar. 31 at 6:40 PM

$KALA - AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry https://finance.yahoo.com/news/red-light-holland-engages-kala-121500405.html

0 · Reply

IChiGOdoranZ Mar. 31 at 6:30 PM

$KALA https://www.tradingview.com/symbols/NASDAQ-KALA/

0 · Reply

Momikhan Mar. 31 at 5:53 PM

$KALA shorts i am digging your grave tonight.

0 · Reply

JustDoItMF Mar. 31 at 5:41 PM

$KALA show me .20s if u really mean it

0 · Reply

SmallCapGrowth Mar. 31 at 5:24 PM

KALA BIO, Inc. (Nasdaq: $KALA) just announced it has delivered an industry-leading autonomous AI research agent via its Researgency.ai platform — marking a major milestone in the $180+ billion agentic AI healthcare revolution! https://x.com/Stock_HighAlert/status/2038611590703087974

0 · Reply

Frankthetank747 Mar. 31 at 5:15 PM

$KALA climb baby, CLIMB!!!

1 · Reply

TheProdigy455 Mar. 31 at 5:10 PM

$KALA give us something good 🤞

0 · Reply

Cheshire1 Mar. 31 at 5:05 PM

$KALA

0 · Reply

BlazingStocks Mar. 31 at 4:03 PM

$KALA News March 18, 2026 Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate https://finance.yahoo.com/news/red-light-holland-engages-kala-121500405.html

0 · Reply

Pennytwits Mar. 31 at 3:34 PM

$KALA an announcement of simply one big company using their AI agents will send it sailing .

0 · Reply

Market Cap	160.12M
Revenue (ttm)	0.00
Net Income (ttm)	-38.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-3.28

Volume	1,956,800
Avg Vol	8,008,320
Day's Range	N/A - N/A
Shares Out	911.33M
Stochastic %K	11%
Beta	-2.37
Analysts	Strong Buy
Price Target	$1.50